• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化患儿呼吸道症状变化对改良版囊性纤维化问卷(CFQ-R)的影响。

Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis.

机构信息

Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Translational Medicine Program, SickKids Research Institute, Toronto, Canada; Royal College of Surgeons in Ireland, Dublin, Ireland; National Children's Research Centre, Crumlin, Dublin, Ireland.

Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Translational Medicine Program, SickKids Research Institute, Toronto, Canada.

出版信息

J Cyst Fibros. 2020 May;19(3):492-498. doi: 10.1016/j.jcf.2020.02.017. Epub 2020 Mar 2.

DOI:10.1016/j.jcf.2020.02.017
PMID:32139196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7329610/
Abstract

INTRODUCTION

The Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory score is a validated and widely used patient-reported outcome. This study aimed to establish changes in the score with acute respiratory events in preschool children with CF and to investigate its' relationship with physiological outcomes.

METHODS

The Parent CFQ-R, multiple breath washout test and spirometry were performed at six study visits over one year. The clinical status of participants, stable or symptomatic, was defined by the patient's physician. Linear regression and distribution-based statistical methods were used to examine the changes in the CFQ-R from the last stable visit and to investigate its relationship with physiological outcomes.

RESULTS

There were 272 stable and 115 symptomatic visits from 78 participants. The mean CFQ-R Respiratory score did not change between consecutive stable visits (-0.73, SD 20.4). The mean (SD) score deteriorated by 15.5 (20.7) points between stable and symptomatic visits and improved by 14.8 (20.1) points between symptomatic and stable follow-up visits. When a clinically important change is defined as 0.5SD change (10-points), the positive predictive value (PPV) was 45% and the negative predictive value (NPV) was 84%. For visits with a 10-point worsening in the CFQ-R Respiratory score and a 15% increase in LCI, the PPV was better (81%) than using either measure alone.

CONCLUSION

The CFQ-R Respiratory score is responsive to acute respiratory events in preschool children with CF and its utility to monitor individual patients is improved when combined with LCI.

摘要

简介

囊性纤维化问卷修订版(CFQ-R)呼吸评分是一种经过验证且广泛使用的患者报告结局。本研究旨在确定 CF 学龄前儿童急性呼吸事件后评分的变化,并探讨其与生理结局的关系。

方法

在一年的六次研究访问中,进行了父母 CFQ-R、多次呼吸冲洗试验和肺活量测定。参与者的临床状况(稳定或有症状)由患者的医生定义。线性回归和基于分布的统计方法用于检查从最后一次稳定访问到 CFQ-R 的变化,并研究其与生理结果的关系。

结果

来自 78 名参与者的 272 次稳定和 115 次有症状访问。连续稳定访问之间的平均 CFQ-R 呼吸评分没有变化(-0.73,SD 20.4)。在稳定和有症状的访问之间,评分平均恶化 15.5(20.7)点,在有症状和稳定的随访访问之间,评分平均改善 14.8(20.1)点。当将临床重要变化定义为 0.5SD 变化(10 分)时,阳性预测值(PPV)为 45%,阴性预测值(NPV)为 84%。对于 CFQ-R 呼吸评分恶化 10 分且 LCI 增加 15%的访问,PPV 优于单独使用任何一种测量方法(81%)。

结论

CFQ-R 呼吸评分对 CF 学龄前儿童的急性呼吸事件敏感,当与 LCI 结合使用时,其监测个体患者的效果得到改善。

相似文献

1
Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis.囊性纤维化患儿呼吸道症状变化对改良版囊性纤维化问卷(CFQ-R)的影响。
J Cyst Fibros. 2020 May;19(3):492-498. doi: 10.1016/j.jcf.2020.02.017. Epub 2020 Mar 2.
2
Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis.比较分析呼吸症状评分以检测囊性纤维化患儿的急性呼吸事件。
J Cyst Fibros. 2023 Mar;22(2):296-305. doi: 10.1016/j.jcf.2022.06.007. Epub 2022 Jun 24.
3
Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis.肺清除指数监测学龄前囊性纤维化患儿肺部加重期的治疗反应。
Thorax. 2018 May;73(5):451-458. doi: 10.1136/thoraxjnl-2017-210979. Epub 2018 Feb 15.
4
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.确定囊性纤维化问卷修订版呼吸症状量表在两组囊性纤维化合并慢性铜绿假单胞菌气道感染患者中的最小临床重要差异分数。
Chest. 2009 Jun;135(6):1610-1618. doi: 10.1378/chest.08-1190. Epub 2009 May 15.
5
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes.儿童囊性纤维化患者的健康相关生活质量及其与健康结果的关联。
J Cyst Fibros. 2020 May;19(3):483-491. doi: 10.1016/j.jcf.2020.02.022. Epub 2020 Mar 9.
6
Quality of life is poorly correlated to lung disease severity in school-aged children with cystic fibrosis.生活质量与学龄期囊性纤维化患儿的肺部疾病严重程度相关性差。
J Cyst Fibros. 2022 May;21(3):e188-e203. doi: 10.1016/j.jcf.2021.11.005. Epub 2021 Nov 17.
7
Longitudinal trends in health-related quality of life in adults with cystic fibrosis.成人囊性纤维化患者健康相关生活质量的纵向趋势。
Chest. 2013 Sep;144(3):981-989. doi: 10.1378/chest.12-1404.
8
Abnormal preschool Lung Clearance Index (LCI) reflects clinical status and predicts lower spirometry later in childhood in cystic fibrosis.异常的学龄前肺部清除指数(LCI)反映了临床状态,并预测了儿童期后期囊性纤维化的肺活量测定值较低。
J Cyst Fibros. 2019 Sep;18(5):721-727. doi: 10.1016/j.jcf.2019.02.007. Epub 2019 Mar 1.
9
Electronic applications for the CFQ-R scoring.电子应用 CFQ-R 评分。
Respir Res. 2017 May 30;18(1):108. doi: 10.1186/s12931-017-0592-z.
10
Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up.囊性纤维化患儿1年随访期间与健康相关生活质量变化相关的因素。
Eur J Pediatr. 2017 Aug;176(8):1047-1054. doi: 10.1007/s00431-017-2928-6. Epub 2017 Jun 9.

引用本文的文献

1
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化:系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
2
Efficacy of Adding Oral N acetyl Cysteine Supplement to the Cystic Fibrosis Treatment Regimen: A Randomized Quasi-Experimental Trial.在囊性纤维化治疗方案中添加口服N-乙酰半胱氨酸补充剂的疗效:一项随机准实验性试验。
J Res Pharm Pract. 2025 Mar 11;13(3):72-77. doi: 10.4103/jrpp.jrpp_54_24. eCollection 2024 Jul-Sep.
3
Polish Cystic Fibrosis Patients' Health-Related Quality of Life and Its Influencing Factors: A Cross-Sectional, Single-Centre Study.波兰囊性纤维化患者的健康相关生活质量及其影响因素:一项横断面单中心研究
Healthcare (Basel). 2024 Jun 12;12(12):1183. doi: 10.3390/healthcare12121183.
4
Pulmonary Function Tests in the Evaluation of Early Lung Disease in Cystic Fibrosis.肺功能测试在囊性纤维化早期肺部疾病评估中的应用
J Clin Med. 2023 Jul 17;12(14):4735. doi: 10.3390/jcm12144735.